Zhongtao Zhang

Zhongtao Zhang

Auto-generated profile, based on publicly available information

Zhongtao Zhang

Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Cancer Invasion and Metastasis Research and National Clinical Research Center for Digestive Diseases, Beijing 100050, P.R. China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2011 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
JSJianning Song
Jianning Song
ZBZhigang Bai
Zhigang Bai
WHWei Han
Wei Han
JZJun Zhang
Jun Zhang
HMHua Meng
Hua Meng
ZZZhongtao Zhang
Zhongtao Zhang

1 January 2019 in Chinese Journal of Cancer Research
Verified
Journal Article
Open access
JYJie Yin
Jie Yin
ZBZhigang Bai
Zhigang Bai
JZJun Zhang
Jun Zhang
ZZZhi Zheng
Zhi Zheng
HYHongwei Yao
Hongwei Yao
C(Chinese Center For Disease Control And Prevention (Cdc) National Center For Chronic And Noncommunicable Disease Control And Prevention (Ncncd)
Chinese Center For Disease Control And Prevention (Cdc) National Center For Chronic And Noncommunicable Disease Control And Prevention (Ncncd)
ObjectiveOur goal is to analyze the trend of colorectal cancer (CRC) regarding the death, incidence and prevalence rates over time, and to provide epidemiological knowledge basis for health policy revision by comparing data about fatal outcomes of CRC in 2017 to those data in 1990, which was extracted from the Global Burden of Disease (GBD). MethodsThe time trend and changes of CRC burden from 1990 to 2017 were measured by using the methods and results from the Institute for Health Metrics and Evaluation (IHME) GBD 2017, based on the rates of death, incidence and prevalence. ResultsThe death rate of CRC is 13.24/100,000, accounting for 1.79% of total deaths in China in 2017. In 1990, CRC ranked 21st in all causes of death in China compared to its 11th ranking in 2017. The death, incidence and prevalence rate of CRC were standardized by the age scale of the global population in 2010, the change of standardized death rate of CRC was not significant, from 9.33/100,000 in 1990 to 10.10/100,000 in 2017. The standardized incidence rate of CRC significantly increased from 12.18/100,000 in 1990 to 22.42/100,000 in 2017. The standardized prevalence rate of CRC significantly increased from 44.55/100,000 in 1990 to 118.40/100,000 in 2017. The trend of the prevalence rate in both genders grow higher in 2017 compared to the 1990, resulting in 141.6%, 209.8% and 189.0% for the studied three age groups (15−49, 50−69 and 70+ years old), respectively. The death rate increased in the age groups of 50−69 and 70+ years in both genders (8.6% and 31.0% respectively), in contrast to a decrease of death rate in the age group of 15−49 years old (−10.8%). ConclusionsChina experienced a stunning increase in terms of incidence and prevalence rate of CRC from 1990 to 2017. To decrease the burden of CRC, prevention and management of known risk factors should be promoted through national polices.

15 October 2013 in Oncology Letters
Verified
Journal Article
Open access
PDF file
JSJianning Song
Jianning Song
ZBZhigang Bai
Zhigang Bai
JZJun Zhang
Jun Zhang
HMHua Meng
Hua Meng
JCJun Cai
Jun Cai
ZZZhongtao Zhang
Zhongtao Zhang
In patients with gastric cancer (GC), circulating microRNA-21 (miR-21) is overexpressed and may serve as a diagnostic biomarker. In the present study, it was hypothesized that the serum miR-21 expression levels were associated with prognosis in the patients with GC. The expression levels of serum miR-21 were measured using quantitative polymerase chain reaction (qPCR) assays in 103 GC patients. Survival and Cox proportional-hazards regression analyses were performed to determine the correlation between serum miR-21 expression levels and prognosis in the patients. The correlation between the serum miR-21 levels and the clinicopathological factors of the patients was also analyzed. Survival curves were not significantly different between the groups exhibiting high and low levels of serum miR-21 expression. High levels of miR-21 in the serum were associated with an increased tumor size and an advanced pT stage. These findings suggest that serum miR-21 could be exploited as a practical biomarker for monitoring tumor burden in patients with GC.

1 January 2009 in World Journal of Gastroenterology
Verified
Journal Article
Open access
WGWei Guo
Wei Guo
WHWei Han
Wei Han
JLJun Liu
Jun Liu
LJLan Jin
Lan Jin
JLJian-She Li
Jian-She Li
YWYu Wang
Yu Wang
Here, we report a case of intrapancreatic accessory spleen confirmed by pathologic diagnosis and discuss its differential diagnosis and surgical management with a review of the literature.

15 May 2014 in Oncology Reports
Verified
Journal Article
Open access
PDF file
YYYun Yang
Yun Yang
ZBZhi-Gang Bai
Zhi-Gang Bai
JYJie Yin
Jie Yin
GWGuo-Cong Wu
Guo-Cong Wu
ZZZhong-Tao Zhang
Zhong-Tao Zhang
Gastric cancer is associated with increased migration and invasion. In the present study, we explored the role of c-Src in gastric cancer cell migration and invasion. BGC-823 gastric cancer cells were used to investigate migration following treatment of these cells with the c-Src inhibitors, PP2 and SU6656. Migration and invasion were analyzed by wound healing and Transwell assays. Western blot analysis was used to detect the expression of MT1-MMP and VEGF-C, while the activity of MMP2 and MMP9 was monitored with gelatin zymography assay. Immunoprecipitation was used to detect interactions among furin, pro-MT1-MMP and pro-VEGF-C. MT1-MMP and VEGF-C expression levels were inhibited by PP2 and SU6656 treatment, in accordance with decreased c-Src activity. Similarly, the zymography assay demonstrated that the activity of MMP2 and MMP9 was decreased following PP2 or SU6656 treatment. Blockade of c-Src also inhibited the invasive and migratory capacity of BGC-823 cells. Notably, c-Src interacted with furin in vivo, while interactions between furin and its substrates, pro-MT1-MMP and pro-VEGF-C, were decreased by c-Src inhibitors. In conclusion, the interaction among furin and pro-MT1-MMP or pro-VEGF-C or other tumor-associated precursor enzymes can be regulated by c-Src activity, thus reducing or changing the expression of these enzymes in order to reduce the development of gastric cancer, invasion and metastasis.

1 June 2015 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
YTYu-Le Tan
Yu-Le Tan
ZBZhi-Gang Bai
Zhi-Gang Bai
WZWei-Long Zou
Wei-Long Zou
XMXue-Mei Ma
Xue-Mei Ma
TWTing-Ting Wang
Ting-Ting Wang
ZZZhong-Tao Zhang
Zhong-Tao Zhang